ZyVersa Therapeutics, Inc. - Common Stock (ZVSA)

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

ZVSA stock results show that ZyVersa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ZVSA stock results show that ZyVersa Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

ZyVersa Therapeutics shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.